OSCR

NRF2 Deletion Results in Mobility Impairment in A53TSyn Model of Synucleinopathy.

Overview

Authors: Noah Gladen-Kolarsky1, Lucas Kuhnau1, Wyatt Hack1, Joseph F Quinn1,2, Nora E Gray1
  1. Department of Neurology, Oregon Health & Science University, Portland, OR 97239, USA; (N.G.-K.)
  2. Parkinson’s Disease Research Education and Clinical Care, Center (PADRECC), VA Portland Healthcare System, Portland, OR 97239, USA
Institutions: Oregon Health & Science University (United States); Portland VA Medical Center (United States); VA Portland Health Care System (United States)
Journal: Antioxidants (Basel, Switzerland), volume 15, issue 8, article 926
Dates: received 1 June 2026; accepted 22 July 2026; published online 25 July 2026
Type: Research article · Language: English
License: CC BY
Identifiers: DOI 10.3390/antiox15080926 · PMID 42650189 · PMCID PMC13509511 · OpenAlex W7171393199
Open access: gold, a free copy (OpenAlex)
Categories: behavior only (modality), human (organism), mouse (organism), Parkinson's (population), cellular / molecular (subfield)
Methods: Statistics, fMRI & imaging
Keywords: Parkinson’s, oxidative stress, mobility, NRF2, alpha-synuclein, mice, tyrosine hydroxylase, A53TSyn, gait, open field
Topic: Genomics, phytochemicals, and oxidative stress (Molecular Biology, Biochemistry, Genetics and Molecular Biology), according to OpenAlex
Funding: Ron and Mary Beamer (Philanthropic donation)
Citations: not cited yet (Europe PMC); 42 references in the paper

Abstract

Parkinson’s Disease (PD) is the second most diagnosed neurological disorder globally, affecting millions of people worldwide. Oxidative stress is implicated in the progression of PD, yet its direct effects on motor function, particularly in the context of synucleinopathy, are not fully understood. Here, we investigated the effects of the loss of the antioxidant regulatory transcription factor NRF2 in the A53TSyn mouse model of synucleinopathy. Motor function was evaluated in separate cohorts of A53TSyn mice without NRF2 (A53TSyn/NRF2KO), as well as A53TSyn mice expressing NRF2 (A53TSyn/NRF2+) and healthy wild-type (WT) mice at four, six, and eight months of age. The overall mobility decreased in A53TSyn/NRF2KO mice relative to WT mice at all ages. Significant alterations in gait were also apparent in A53TSyn/NRF2KO mice compared to A53TSyn mice without NRF2 deletion. Expression of tyrosine hydroxylase (TH) was also quantified in the brains of those mice. While there were no differences in cortical pSyn expression between A53TSyn/NRF2+ and A53TSyn/NRF2KO mice, a reduction in TH abundance in the striatum was evident in A53TSyn/NRF2KO mice at all ages. In summary, our data suggest that NRF2 plays a role in maintaining mobility and gait in the context of synucleinopathy and may represent a therapeutic target to mitigate mobility decline in PD-affected individuals.

Reproduced under the paper's license (CC BY), from the paper cited above.

Code

The paper links to its data and to no code of its authors: see the Data section.

Tracing map

A tracing map links a paper to the code its authors published: this paper has none, so it has no map.

Data

Datasets cited

Data Availability Statement

The raw data supporting the conclusions of this article will be madeavailable by the authors on request.

Reproduced under the paper's license (CC BY), from the paper cited above.

Versions

The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.

Version 1, 27 September 2026: the first record

Recorded: type, language, journal, volume, issue, pages, dates, 5 authors, 10 keywords, 1 funder, 40 references.

Cite

This paper

Gladen-Kolarsky, N., Kuhnau, L., Hack, W., Quinn, J. F., & Gray, N. E. (2026). NRF2 Deletion Results in Mobility Impairment in A53TSyn Model of Synucleinopathy. Antioxidants (Basel, Switzerland), 15(8), 926. https://doi.org/10.3390/antiox15080926

BibTeX

@article{gladenkolarsky2026nrf2,
author = {Gladen-Kolarsky, Noah and Kuhnau, Lucas and Hack, Wyatt and Quinn, Joseph F and Gray, Nora E},
title = {{NRF2 Deletion Results in Mobility Impairment in A53TSyn Model of Synucleinopathy}},
journal = {Antioxidants (Basel, Switzerland)},
year = {2026},
month = jul,
volume = {15},
number = {8},
pages = {926},
publisher = {Multidisciplinary Digital Publishing Institute (MDPI)},
issn = {2076-3921},
doi = {10.3390/antiox15080926},
url = {https://doi.org/10.3390/antiox15080926},
pmid = {42650189},
pmcid = {PMC13509511}
}

RIS

TY - JOUR
AU - Gladen-Kolarsky, Noah
AU - Kuhnau, Lucas
AU - Hack, Wyatt
AU - Quinn, Joseph F
AU - Gray, Nora E
TI - NRF2 Deletion Results in Mobility Impairment in A53TSyn Model of Synucleinopathy
T2 - Antioxidants (Basel, Switzerland)
J2 - Antioxidants (Basel)
PY - 2026
DA - 2026/07/25
VL - 15
IS - 8
SP - 926
SN - 2076-3921
PB - Multidisciplinary Digital Publishing Institute (MDPI)
DO - 10.3390/antiox15080926
UR - https://doi.org/10.3390/antiox15080926
LA - en
ER -

CSL-JSON

{
"id": "10.3390/antiox15080926",
"type": "article-journal",
"title": "NRF2 Deletion Results in Mobility Impairment in A53TSyn Model of Synucleinopathy",
"container-title": "Antioxidants (Basel, Switzerland)",
"author": [
{
"family": "Gladen-Kolarsky",
"given": "Noah"
},
{
"family": "Kuhnau",
"given": "Lucas"
},
{
"family": "Hack",
"given": "Wyatt"
},
{
"family": "Quinn",
"given": "Joseph F"
},
{
"family": "Gray",
"given": "Nora E"
}
],
"container-title-short": "Antioxidants (Basel)",
"volume": "15",
"issue": "8",
"page": "926",
"DOI": "10.3390/antiox15080926",
"PMID": "42650189",
"PMCID": "PMC13509511",
"ISSN": "2076-3921",
"publisher": "Multidisciplinary Digital Publishing Institute (MDPI)",
"URL": "https://doi.org/10.3390/antiox15080926",
"language": "en",
"issued": {
"date-parts": [
[
2026,
7,
25
]
]
}
}

Similar papers

The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.

[1] doi:10.1186/s12974-025-03455-x
Repurposing of epalrestat for neuroprotection in parkinson's disease via activation of the KEAP1/Nrf2 pathway.
Journal: Journal of neuroinflammation
In common: Parkinson's, mouse, cellular / molecular, 4 references
[2] doi:10.1002/ctm2.70420
YOD1 regulates oxidative damage of dopamine neurons in Parkinson's disease by deubiquitinating PKM2.
Journal: Clinical and translational medicine
In common: Parkinson's, mouse, cellular / molecular, 4 references
[3] doi:10.1038/s41531-024-00763-6
Neuroprotection of low dose carbon monoxide in Parkinson's disease models commensurate with the reduced risk of Parkinson's among smokers.
Journal: NPJ Parkinson's disease
In common: Parkinson's, 3 references
[4] doi:10.1186/s12974-023-02776-z
PARK7/DJ-1 in microglia: implications in Parkinson's disease and relevance as a therapeutic target.
Journal: Journal of neuroinflammation
In common: Parkinson's, cellular / molecular, 3 references
[5] doi:10.1002/jev2.12397
Recommendations for reproducibility of cerebrospinal fluid extracellular vesicle studies.
Journal: Journal of extracellular vesicles
In common: cellular / molecular, author Joseph F Quinn
[6] doi:10.1038/s41531-024-00697-z
GUCY2C signaling limits dopaminergic neuron vulnerability to toxic insults.
Journal: NPJ Parkinson's disease
In common: Parkinson's, mouse, cellular / molecular, 2 references
[7] doi:10.1177/0271678x251338952
Neural and vascular contributions to sensory impairments in a human alpha-synuclein transgenic mouse model of Parkinson's disease.
Journal: Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism
In common: Parkinson's, mouse, cellular / molecular, 2 references
[8] doi:10.1038/s41467-023-42876-1
Knockout or inhibition of USP30 protects dopaminergic neurons in a Parkinson's disease mouse model.
Journal: Nature communications
In common: Parkinson's, mouse, cellular / molecular, 2 references
[9] doi:10.1038/s44328-025-00057-8
Organic electrolyte gated field effect transistor for detecting alpha synuclein longitudinally in Parkinsonism mouse model.
Journal: Npj biosensing
In common: Parkinson's, mouse, 2 references
[10] doi:10.1038/s41531-022-00282-2
Transcriptional analysis of peripheral memory T cells reveals Parkinson's disease-specific gene signatures.
Journal: NPJ Parkinson's disease
In common: Parkinson's, cellular / molecular, 2 references

Contribute

The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.

Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.

Request its removal

To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).

Discussion, reproductions, activity

Discussion: code errors and mismatches between the code and the paper about this paper and its code, from readers and its authors, beside the paper and its tracing map.

Reproductions: reports from readers who ran the authors' code and did not get the paper's result, what they ran, with which environment, commit and data.

Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.